薬理ゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D005-00810 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医療・製薬

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、薬理ゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）の世界市場を広く調査・分析し、今後の市場展望をまとめております。薬理ゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）の種類別市場規模（PCR、In-situハイブリダイゼーション、免疫組織化学、シーケンシング、その他）、用途別市場規模（腫瘍学、神経疾患、循環器疾患、免疫疾患、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Qiagen NV、Pfizer、F Hoffman La Roche、GE Healthcare、Leica Biosystems Nussloch GmBH、Agilent Technologies、Thermo Fisher Scientific Inc.、Foundation Medicine ・地域別グローバル市場分析 2015年-2020年 ・薬理ゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）の北米市場（アメリカ、カナダ、メキシコ） ・薬理ゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・薬理ゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・薬理ゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）の南米市場（ブラジル、アルゼンチン） ・薬理ゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：PCR、In-situハイブリダイゼーション、免疫組織化学、シーケンシング、その他 ・用途別分析：腫瘍学、神経疾患、循環器疾患、免疫疾患、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論

Market Overview
The global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 6.6% in the forecast period of 2020 to 2025 and will expected to reach USD 6615.9 million by 2025, from USD 5125 million in 2019.

The Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market has been segmented into:
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others

By Application, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) has been segmented into:
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market presented in the report. This section sheds light on the sales growth of different regional and country-level Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market.

The report offers in-depth assessment of the growth and other aspects of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share Analysis
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) sales, revenue and market share for each player covered in this report.

The major players covered in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) are:
Qiagen NV
Pfizer
F Hoffman La Roche
GE Healthcare
Leica Biosystems Nussloch GmBH
Agilent Technologies
Thermo Fisher Scientific Inc.
Foundation Medicine

レポート目次

---

Table of Contents

1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Overview
1.1 Product Overview and Scope of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx)
1.2 Classification of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Type
1.2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Type in 2019
1.2.3 PCR
1.2.4 In-situ Hybridization
1.2.5 Immunohistochemistry
1.2.6 Sequencing
1.2.7 Others
1.3 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market by Application
1.3.1 Overview: Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Oncology
1.3.3 Neurological Disorders
1.3.4 Cardiovascular Disease
1.3.5 Immunological Disorders
1.3.6 Others
1.4 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market by Regions
1.4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Status and Prospect (2015-2025)
2 Company Profiles
2.1 Qiagen NV
2.1.1 Qiagen NV Details
2.1.2 Qiagen NV Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Qiagen NV SWOT Analysis
2.1.4 Qiagen NV Product and Services
2.1.5 Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Pfizer SWOT Analysis
2.2.4 Pfizer Product and Services
2.2.5 Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
2.3 F Hoffman La Roche
2.3.1 F Hoffman La Roche Details
2.3.2 F Hoffman La Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 F Hoffman La Roche SWOT Analysis
2.3.4 F Hoffman La Roche Product and Services
2.3.5 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
2.4 GE Healthcare
2.4.1 GE Healthcare Details
2.4.2 GE Healthcare Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 GE Healthcare SWOT Analysis
2.4.4 GE Healthcare Product and Services
2.4.5 GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
2.5 Leica Biosystems Nussloch GmBH
2.5.1 Leica Biosystems Nussloch GmBH Details
2.5.2 Leica Biosystems Nussloch GmBH Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Leica Biosystems Nussloch GmBH SWOT Analysis
2.5.4 Leica Biosystems Nussloch GmBH Product and Services
2.5.5 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
2.6 Agilent Technologies
2.6.1 Agilent Technologies Details
2.6.2 Agilent Technologies Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Agilent Technologies SWOT Analysis
2.6.4 Agilent Technologies Product and Services
2.6.5 Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
2.7 Thermo Fisher Scientific Inc.
2.7.1 Thermo Fisher Scientific Inc. Details
2.7.2 Thermo Fisher Scientific Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Thermo Fisher Scientific Inc. SWOT Analysis
2.7.4 Thermo Fisher Scientific Inc. Product and Services
2.7.5 Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
2.8 Foundation Medicine
2.8.1 Foundation Medicine Details
2.8.2 Foundation Medicine Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Foundation Medicine SWOT Analysis
2.8.4 Foundation Medicine Product and Services
2.8.5 Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players Market Share
3.2.2 Top 10 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Market Share by Regions
4.2 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
4.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
4.5 South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
5 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries
5.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
5.2 USA Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
5.3 Canada Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
5.4 Mexico Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
6 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries
6.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
6.2 Germany Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
6.3 UK Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
6.4 France Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
6.5 Russia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
6.6 Italy Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries
7.1 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
7.2 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
7.3 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
7.4 Korea Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
7.5 India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
8 South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries
8.1 South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
8.2 Brazil Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
8.3 Argentina Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Countries
9.1 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
9.2 Saudi Arabia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
9.3 UAE Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
9.4 Egypt Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
9.5 South Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Market Share by Type (2015-2020)
10.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast by Type (2019-2024)
10.3 PCR Revenue Growth Rate (2015-2025)
10.4 In-situ Hybridization Revenue Growth Rate (2015-2025)
10.5 Immunohistochemistry Revenue Growth Rate (2015-2025)
10.6 Sequencing Revenue Growth Rate (2015-2025)
10.7 Others Revenue Growth Rate (2015-2025)
11 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Segment by Application
11.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Application (2015-2020)
11.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast by Application (2019-2024)
11.3 Oncology Revenue Growth (2015-2020)
11.4 Neurological Disorders Revenue Growth (2015-2020)
11.5 Cardiovascular Disease Revenue Growth (2015-2020)
11.6 Immunological Disorders Revenue Growth (2015-2020)
11.7 Others Revenue Growth (2015-2020)
12 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Forecast (2021-2025)
12.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Forecast (2021-2025)
12.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Forecast by Regions (2021-2025)
12.3 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
12.4 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
12.6 South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Qiagen NV Corporate Information, Location and Competitors
Table 6. Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business
Table 7. Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018)
Table 8. Qiagen NV SWOT Analysis
Table 9. Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions
Table 10. Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Pfizer Corporate Information, Location and Competitors
Table 12. Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business
Table 13. Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2018-2019)
Table 14. Pfizer SWOT Analysis
Table 15. Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions
Table 16. Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. F Hoffman La Roche Corporate Information, Location and Competitors
Table 18. F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business
Table 19. F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018)
Table 20. F Hoffman La Roche SWOT Analysis
Table 21. F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions
Table 22. F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. GE Healthcare Corporate Information, Location and Competitors
Table 24. GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business
Table 25. GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018)
Table 26. GE Healthcare SWOT Analysis
Table 27. GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions
Table 28. GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Leica Biosystems Nussloch GmBH Corporate Information, Location and Competitors
Table 30. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business
Table 31. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018)
Table 32. Leica Biosystems Nussloch GmBH SWOT Analysis
Table 33. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions
Table 34. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Agilent Technologies Corporate Information, Location and Competitors
Table 36. Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business
Table 37. Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018)
Table 38. Agilent Technologies SWOT Analysis
Table 39. Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions
Table 40. Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Thermo Fisher Scientific Inc. Corporate Information, Location and Competitors
Table 42. Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business
Table 43. Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018)
Table 44. Thermo Fisher Scientific Inc. SWOT Analysis
Table 45. Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions
Table 46. Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Foundation Medicine Corporate Information, Location and Competitors
Table 48. Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Major Business
Table 49. Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Total Revenue (USD Million) (2017-2018)
Table 50. Foundation Medicine SWOT Analysis
Table 51. Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product and Solutions
Table 52. Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) by Players (2015-2020)
Table 54. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Players (2015-2020)
Table 55. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) by Regions (2015-2020)
Table 56. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Regions (2015-2020)
Table 57. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
Table 58. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020)
Table 59. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) by Countries (2015-2020)
Table 60. Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) by Countries (2015-2020)
Table 61. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Countries (2015-2020)
Table 62. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020)
Table 63. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) by Countries (2015-2020)
Table 64. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020)
Table 65. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) by Type (2015-2020)
Table 66. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Type (2015-2020)
Table 67. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Forecast by Type (2021-2025)
Table 68. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue by Application (2015-2020)
Table 69. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Application (2015-2020)
Table 70. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Forecast by Application (2021-2025)
Table 71. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Picture
Figure 2. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Type in 2019
Figure 3. PCR Picture
Figure 4. In-situ Hybridization Picture
Figure 5. Immunohistochemistry Picture
Figure 6. Sequencing Picture
Figure 7. Others Picture
Figure 8. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Application in 2019
Figure 9. Oncology Picture
Figure 10. Neurological Disorders Picture
Figure 11. Cardiovascular Disease Picture
Figure 12. Immunological Disorders Picture
Figure 13. Others Picture
Figure 14. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (USD Million) and Growth Rate (2015-2025)
Figure 15. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Players in 2019
Figure 22. Global Top 5 Players Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share in 2019
Figure 23. Global Top 10 Players Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share in 2019
Figure 24. Key Players Market Share Trend
Figure 25. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 26. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Regions (2015-2020)
Figure 27. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Regions in 2018
Figure 28. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 29. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 30. Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 31. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 32. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 33. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020)
Figure 34. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries in 2019
Figure 35. USA Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 36. Canada Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 37. Mexico Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 38. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020)
Figure 39. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries in 2019
Figure 40. Germany Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 41. UK Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 42. France Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 43. Russia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 44. Italy Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020)
Figure 46. Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries in 2019
Figure 47. China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 48. Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 49. Korea Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 50. India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 51. Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 52. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020)
Figure 53. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries in 2019
Figure 54. Brazil Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 55. Argentina Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 56. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries (2015-2020)
Figure 57. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Countries in 2019
Figure 58. Saudi Arabia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 59. UAE Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 60. Egypt Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 61. South Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue and Growth Rate (2015-2020)
Figure 62. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Type (2015-2020)
Figure 63. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Type in 2019
Figure 64. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share Forecast by Type (2021-2025)
Figure 65. Global PCR Revenue Growth Rate (2015-2020)
Figure 66. Global In-situ Hybridization Revenue Growth Rate (2015-2020)
Figure 67. Global Immunohistochemistry Revenue Growth Rate (2015-2020)
Figure 68. Global Sequencing Revenue Growth Rate (2015-2020)
Figure 69. Global Others Revenue Growth Rate (2015-2020)
Figure 70. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Application (2015-2020)
Figure 71. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Share by Application in 2019
Figure 72. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share Forecast by Application (2021-2025)
Figure 73. Global Oncology Revenue Growth Rate (2015-2020)
Figure 74. Global Neurological Disorders Revenue Growth Rate (2015-2020)
Figure 75. Global Cardiovascular Disease Revenue Growth Rate (2015-2020)
Figure 76. Global Immunological Disorders Revenue Growth Rate (2015-2020)
Figure 77. Global Others Revenue Growth Rate (2015-2020)
Figure 78. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 79. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 80. Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share Forecast by Regions (2021-2025)
Figure 81. North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
Figure 82. Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
Figure 83. Asia-Pacific Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
Figure 84. South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
Figure 85. Middle East and Africa Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Forecast (2021-2025)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel

---